Aduro Biotech

📍 United States👥 83 employees💰 Last funded 2014
Biotechnology🌐 aduro.com
Website LinkedIn
Aduro Biotech, Inc. (Nasdaq: ADRO) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies that are designed to harness the body’s natural immune system for the treatment of patients with challenging diseases. Aduro's product candidates in the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways are being investigated in cancer, autoimmune and inflammatory diseases. ADU-S100 (MIW815), which potentially activates the intracellular STING receptor for a potent tumor-specific immune response, is being evaluated in patients with cutaneously accessible metastatic solid tumors or lymphomas. BION-1301, a fully blocking monoclonal antibody that blocks APRIL binding to both the BCMA and TACI receptors, is being evaluated for the treatment of IgA nephropathy. Aduro is collaborating with a number of leading global pharmaceutical companies to help expand and drive its product pipeline.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Aduro Biotech?
Aduro Biotech has 1 investors on record on gritt.io.
When did Aduro Biotech last raise funding?
The most recent investment in Aduro Biotech recorded on gritt.io was in 2014.
What industry is Aduro Biotech in?
Aduro Biotech operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Aduro Biotech based?
Aduro Biotech is headquartered in United States.